Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a Company presentation at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 3:00 p.m. ET in New York, NY.

Earlier today, Cara announced positive topline results from its Phase 2 dose-ranging trial of Oral KORSUVA™ for the treatment of pruritus in patients with stage III-V (moderate-to-severe) chronic kidney disease. Oral KORSUVA met the primary endpoint of statistically significant reduction in mean Worst Itching Intensity Numeric Rating Scale (WI-NRS) scores with the 1 mg tablet strength versus placebo after the 12-week treatment period (p=0.018). Oral KORSUVA was generally well-tolerated.

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the peripheral nervous system, and on immune cells. In a Phase 3 and two Phase 2 trials, KORSUVA (CR845/difelikefalin) Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP), and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with chronic kidney disease, atopic dermatitis, and primary biliary cholangitis.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:Jane UrheimStern Investor Relations, Inc. 212-362-1200 [e-mail]

MEDIA CONTACT:Annie Starr6 Degrees973-415-8838 [e-mail]